These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16649633)

  • 1. Pfizer's puzzle.
    Simons J
    Fortune; 2006 Apr; 153(7):152-4, 156. PubMed ID: 16649633
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 3. Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine. Interview by Steve Carney.
    Corr PB
    Drug Discov Today; 2005 Aug; 10(15):1017-20. PubMed ID: 16055016
    [No Abstract]   [Full Text] [Related]  

  • 4. Pfizer's home remedy.
    Abkowitz A
    Fortune; 2009 Aug; 160(4):82-4, 86. PubMed ID: 19728588
    [No Abstract]   [Full Text] [Related]  

  • 5. Pfizer's DRUMBEAT program.
    Chapman KG
    J Parenter Drug Assoc; 1980; 34(3):217-23. PubMed ID: 6901776
    [No Abstract]   [Full Text] [Related]  

  • 6. Growing against the grain.
    Boyle M
    Fortune; 2004 May; 149(9):148-9, 152, 154 passim. PubMed ID: 15124331
    [No Abstract]   [Full Text] [Related]  

  • 7. Big Pharma's small wonder.
    Fry E
    Fortune; 2014 Jun; 169(8):178-84, 186. PubMed ID: 25211849
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals. Pfizer's shakeup means less money for research.
    Kean S
    Science; 2011 Feb; 331(6018):658. PubMed ID: 21310976
    [No Abstract]   [Full Text] [Related]  

  • 9. Will R&D make Merck hot again?
    Simons J
    Fortune; 2002 Jul; 146(1):89-90, 92, 94. PubMed ID: 12119729
    [No Abstract]   [Full Text] [Related]  

  • 10. Stockholders protest Pfizer's drug prices.
    Lenzer J
    CMAJ; 2004 Jul; 171(1):24. PubMed ID: 15238486
    [No Abstract]   [Full Text] [Related]  

  • 11. SmithKline's ulcer medicine "holy war".
    Dreyfuss J
    Fortune; 1983 Sep; 108(6):129-30, 134-6. PubMed ID: 10262256
    [No Abstract]   [Full Text] [Related]  

  • 12. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 13. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 14. Bet on one big idea--or diversify?
    Stuart TE
    Harv Bus Rev; 2013 Nov; 91(11):131-5. PubMed ID: 24340875
    [No Abstract]   [Full Text] [Related]  

  • 15. Is it too late to save Schering?
    Simons J
    Fortune; 2003 Sep; 148(5):145-6, 148, 150. PubMed ID: 14509911
    [No Abstract]   [Full Text] [Related]  

  • 16. Inside Pfizer's palace coup. Did CEO Jeff Kindler get pushed out because he was shaking up the dysfunctional pharmaceutical giant--or because he was an ineffective leader?
    Elkind P; Reingold J; Burke D
    Fortune; 2011 Aug; 164(3):76-91. PubMed ID: 21879700
    [No Abstract]   [Full Text] [Related]  

  • 17. Stop the dollar worshiping.
    Keller BR
    Tex Med; 2001 Feb; 97(2):13-4. PubMed ID: 11233053
    [No Abstract]   [Full Text] [Related]  

  • 18. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 19. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 20. Amgen's NESP victory cuts out Johnson & Johnson.
    Fürst I
    Nat Biotechnol; 1999 Feb; 17(2):124. PubMed ID: 10052335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.